ALFA Finder| Margins | Margins expected to contract in FY27 before recovery in FY28. |
|---|---|
| Demand visibility | Visibility in oncology and GLP-1 (semaglutide) launches in emerging markets. |
| Management confidence | Confident in long-term diversification strategy despite immediate cyclical dip. |
Growth
FY26 revenue dropped to ₹4,375.9cr from ₹4,784cr; PAT fell to ₹1,418.5cr from ₹1,883.4cr.
Outlook
FY27 guidance: ₹3,400-3,500cr revenue and ₹700-750cr PAT. Expecting 15-25% CAGR growth from FY28 onwards.
Risks
Revlimid revenue decline, Middle East war impacting freight costs, and high competitive intensity in US generics.
Last quarter's promises, checked
Delivered
- Guided H1 PAT ₹1,000cr → delivered ₹1,000cr (= BEAT)
- Guided H2 PAT ₹270-300cr → delivered ₹418.5cr (= BEAT)
- Guided FY26 PAT ₹1,275-1,300cr → delivered ₹1,418.5cr (= BEAT)
Partly delivered
- Targeted Semaglutide India launch March/April 2026 → Launched in Q4 (= PARTIAL)
Missed
- Guided FY26 Revenue ~₹4,600cr → delivered ₹4,375.9cr (= MISS)
Earnings Call filed with BSE, NSE: NATCOPHARM. Summary written with AI assistance from the document.
Natco Pharma Ltd: key numbers
- Share price
- ₹808.95
- Market cap
- ₹15,869 Cr
- Revenue (annual)
- ₹4,078 Cr
- Net profit (annual)
- ₹1,418 Cr
- P/E (TTM)
- 13.9×Sector 43.8×
- Promoter holding
- 46.22%-3.20% QoQ
- FII holding
- 15.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Natco Pharma Ltd
All →Natco Pharma Share Pledge
Natco Pharma promoter V.C. Nannapaneni pledged 8,50,000 equity shares to Bajaj Financial Securities Limited. The pledge supports the promoter's subscription to the company's Rights Issue.
Natco Pharma Other Announcement
Natco Pharma filed its shareholding pattern with a reporting date of 23 October 2026. Promoter and promoter group hold about 46% of total equity.
Natco Pharma Capital Structure Change
Natco Pharma allotted 5,86,666 equity shares to promoter Venkaiah Chowdary Nannapaneni via its rights issue, valued at ~₹44 Crore. This lifts his stake to 14.60%.
- Value
- ₹44.00 Cr
Natco Pharma Employee Stock Options
Natco Pharma's insiders, including promoters and directors, were allotted equity shares. This allotment increases their total shareholding in the company.
- Value
- ₹144.2 Cr
Natco Pharma Board Meeting Date
Natco Pharma will hold a board meeting on 13 November 2026 to consider unaudited quarterly results and an interim dividend. Trading window closed until 15 November 2026.
Natco Pharma Capital Structure Change
Natco Pharma's ₹1,279.4 Crore rights issue closed on October 22, 2026. Shares were priced at ₹750 each on a ₹2 face value.
- Value
- ₹1,279 Cr